Trial Profile
A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BRAVERY
- 24 Sep 2021 Status changed from active, no longer recruiting to completed.
- 17 Aug 2020 Planned End Date changed from 31 Dec 2019 to 18 Sep 2020.
- 04 Jul 2020 Primary endpoint (Confirmed objective response rate(ORR) by investigators assessment) has not been met as per Results presented at the 22nd World Congress on Gastrointestinal Cancer.